

- Granulocyte colony-stimulating factor (G-CSF) therapy (*Cont.*):
 indications for, 103e-23–24, 103e-24t
 for myelodysplasia, 671
 for neutropenia, 423
 for sulfur mustard exposure, 262e-4
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), 372e-11t, 414f, 416–417
- Granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy
 for AML, 686
 in HSCT, 139e-1–2
 indications for, 103e-23–24, 103e-24t
- Granulocytic sarcoma (cutaneous chloroma), 365
- Granulocytopenia, in cancer patient, 486, 486t, 488
- Granulocytosis, 612, 612t, 634
- Granuloma(s)
Candida, 1343
 diagnosis of, 342
 formation of, 145e-10
 hepatic, 367e-3, 2026t
 palisading, 364
 periapical, 236
 pyogenic, 237
 in sarcoidosis, 2205. *See also* Sarcoidosis
 in schistosomiasis, 1426
 tick-bite, 2745
 in vasculitis, 2180–2181
- Granuloma annulare, 355, 356t, 2430
- Granuloma inguinale. *See* Donovanosis
- Granulomatosis
 bronchocentric, 1716
 eosinophilic, with allergic angitis. *See* Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
 lymphomatoid, 135e-3, 1716, 2184
- Granulomatosis infantiseptica, 983
- Granulomatosis with polyangiitis (Wegener's), 2182
 clinical features of, 1840, 2183–2184, 2183t
 bacterial pneumonia, 386e-2f
 bilateral nodular infiltrates, 386e-1f
 chronic meningitis, 909t
 cutaneous, 366, 2184
 hemoptysis, 245
 intracranial infarcts, 2568–2569
 ocular, 200, 386e-2f, 2184
 oral, 237
 renal, 1835t, 1840, 2184
 saddle-nose deformity, 1443, 2183
 sinusitis, 226, 386e-3f
 definition of, 2182
 diagnosis of, 2184
 ANCA, 2184
 chest imaging, 386e-1, 386e-1f
 CT, 386e-1f, 386e-2f, 386e-3f, 2183f
 lung biopsy, 386e-1, 386e-5f
 lung histology, 2182, 2183f
 renal biopsy, 62e-5f, 386e-1, 386e-6f, 1840
 differential diagnosis of, 2184, 2204
 incidence and prevalence of, 2182
 pathogenesis of, 377e-4, 2180, 2182–2183
 pathology of, 2182–2183, 2183f
 treatment of
 cyclophosphamide induction, 2185
 methotrexate induction, 2185
 organ-specific, 2185–2186
 principles of, 2181–2182, 2184–2185
 remission maintenance, 2185
 rituximab induction, 2185
 toxicities of, 2182t
 trimethoprim-sulfamethoxazole, 2185
- Granulomatous (necrotizing) arteritis, 2567–2568
- Granulomatous diseases, chronic. *See* Chronic granulomatous diseases (CGDs)
- Granulomatous gastritis, 1932
- Granulomatous interstitial nephritis, 1857f, 1858
- Granulomatous myocarditis, 1561
- Granulomatous (subacute) thyroiditis, 2298–2299, 2298f
- Granulosa cell(s), 2375
- Granulosa cell tumor, 594
- Grapefruit juice, 42, 246e-9, 1590
- Graphesthesia, 160, 2539
- Grasp reflex, 2539
- Graves' disease, 2293. *See also* Thyrotoxicosis
 anti-*Yersinia* antibodies in, 1077
 APS-2 and, 2346, 2347t
 in children, 2297
 clinical course of, 2296
 clinical features of, 2294
 goiter, 2301
 ophthalmopathy. *See* Graves' ophthalmopathy
 pretibial myxedema, 76e-16f
 signs and symptoms, 2294t
 thyroid acropachy, 2245, 2295f
 thyroid dermopathy, 2295f
 diagnosis of, 2254t, 2288, 2295, 2295f
 differential diagnosis of, 2295–2296
 edema in, 253
 epidemiology of, 2293
 genetic considerations in, 2294
 insulin autoimmune syndrome in, 2348
 pathogenesis of, 372e-24t, 2251, 2294
 in pregnancy, 2297
 prevalence of, 2254t
 radiation therapy-related, 623
 remission rates, 2296
 thymic tumors in, 2348
 treatment of, 2296–2297
- Graves' ophthalmopathy
 clinical course of, 2296
 clinical features of, 41e-1v, 207, 2294–2295, 2295f
 diagnosis of, 207
 pathogenesis of, 462e-18, 2294
 treatment of, 207, 2297
- Gray (Gy), 103e-4, 263e-1
- Gray hepatization, 804
- Great saphenous vein, ligation of, 1652–1653
- Green bottle fly, 2747
- Greenhouse gases, 151e-1, 151e-2f, 151e-2t
- Green nail syndrome, 1047
- Green tea extracts, 351
- GRFoma (growth hormone–releasing factor tumor), 559t, 571
- Griffiths' point, 1979, 1979f
- Griselli syndrome, 375e-2
- Griseofulvin, 350, 350t, 355t, 1331
- GRN gene mutations, 172t, 2603
- Gross cystic disease fibrous protein, 120e-2, 120e-2t
- Ground-glass opacity
 in ARDS, 308e-10f
 bleomycin-related, 621
 in granulomatosis with polyangiitis, 386e-2f
 pulmonary, 515–516, 517f, 1689
- Group A *Streptococcus* (GAS) infections, 963.
See also *Streptococcus pyogenes*
 asymptomatic carrier of, 966
 in cancer patient, 486
 cellulitis, 830, 967–968
 complications of. *See* Poststreptococcal glomerulonephritis; Rheumatic fever
 diagnosis of, 150e-2, 150e-6, 232–233
 ecthyma, 349
 endocarditis. *See* Infective endocarditis
 epidemiology of, 963–964
 epiglottitis, 234
 erysipelas. *See* Erysipelas
 global considerations in, 964, 964f, 966
 health care–associated, 913
 impetigo. *See* Impetigo
 infection control measures, 917
 joints, 834. *See also* Infectious (septic) arthritis
 laryngitis, 234
 myositis, 831, 968
 necrotizing fasciitis. *See* Necrotizing fasciitis
 pathogenesis of, 964–965
 pharyngitis. *See* Pharyngitis, streptococcal
 pneumonia, 968
 prevention of, 969
- Group B *Streptococcus* (GBS) infections
 cellulitis, 830, 970
 clinical syndromes, 970
 diagnosis of, 150e-8, 969
 endocarditis. *See* Infective endocarditis
 epidemiology of, 969
 myocarditis, 992
 neonatal, 970
 pharyngitis, 231
 in pregnancy, 50, 970
 prevention of, 970
 treatment of, 50, 970
- Group C *Streptococcus* infections, 969
- Group D *Streptococcus* infections, 486t, 490, 539, 971
- Group G *Streptococcus* infections, 231, 969
- Growth
 disorders of, 2257–2258. *See also* Short stature
 hormones in, 400e-5. *See also* Growth hormone (GH)
 somatic, skeletal maturation and, 2257
 in type Ia glycogen storage disease, 436e-5f
- Growth hormone (GH), 401e-3
 action of, 401e-3
 Creutzfeldt-Jakob disease after, 453e-3
 ectopic production of, 609t
 effectors and signaling pathways of, 400e-1t
 expression and regulation of, 401e-1t
 insensitivity, 2258
 laboratory evaluation of, 2258t
 in obesity, 415e-4
 for osteoporosis management/prevention, 2503
 in puberty, 2379
 recombinant
 for adult growth hormone deficiency, 2260, 2260f
 adverse effects of, 2260
 for growth hormone deficiency in children, 2259
 secretion of, 401e-3
 synthesis of, 401e-3
- Growth hormone (GH) deficiency
 in adults, 2259–2260, 2259t, 2260f
 in children, 2257–2258, 2259t, 2433
 idiopathic, 2258
 laboratory investigation of, 2259
- Growth hormone (GH) gene mutations, 434
- Growth hormone (GH) receptor antagonists, for acromegaly, 2271
- Growth hormone–releasing factor tumors (GRFomas), 559t, 571
- Growth hormone-releasing hormone (GHRH), 401e-3, 609t, 2258, 2265
- Growth hormone-releasing hormone (GHRH) agonists, 327
- GRO- α /MGSA, 372e-12t
- GRO- β /MIP-2 α , 372e-12t
- GSD. *See* Glycogen storage diseases (GSD)
- GSS (Gerstmann-Sträussler-Scheinker) disease, 453e-1t, 453e-4
- GSTP1* gene promoter, 580
- GTP cyclohydrolase I deficiency, 434e-2t
- Guama virus, 1309t
- Guanabenz, 473e-9t
- Guanarito virus, 1306t
- Guanethidine, 253t
- Guanfacine, 468e-3, 1624t, 2623
- Guanine, 426
- Guided imagery, 14e-1t
- Guillain-Barré syndrome (GBS), 2694
 after infectious diarrhea, 855t
 antecedent events, 2695
 vs. botulism, 989